Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate an investigational drug (DFMO) in
combination with bortezomib, for relapsed and refractory neuroblastoma. DFMO is an
investigational drug because it has not been approved by the U.S. Food and Drug
Administration (FDA). This study will look at the safety and tolerability of DFMO in
combination with bortezomib as well as the tumors response to this study drug.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Giselle SaulnierSholler Giselle Sholler
Collaborators:
Beat NB Cancer Foundation Because of Ezra K C Pharmaceuticals Inc.